Literature DB >> 18399712

Free drug metabolic clearance in elderly people.

Jennifer M Butler1, Evan J Begg.   

Abstract

The question of whether metabolic drug clearance is decreased in elderly people has been the subject of considerable debate and is very important because clearance is a determinant of dosing. Drug clearance has been shown to be consistently impaired for flow-limited (high-clearance) drugs, but there have been conflicting results for capacity-limited (low-clearance) drugs. A limitation of the studies of capacity-limited drugs is that most have estimated clearance based on total drug concentrations (protein-bound plus free). Total drug clearance reflects both the intrinsic clearance of free drug and the extent of protein binding. Total clearance is a valid measure for capacity-limited drugs with low protein binding and appears to be consistently impaired in elderly subjects. For phenazone [antipyrine] (fraction unbound [f(u)] >0.9), seven studies have demonstrated statistical reductions in clearance of 20-52%. For theophylline (f(u) 0.6), five studies have demonstrated reductions in clearance of 22-35%. For paracetamol [acetaminophen] (f(u) 0.8), the clearance of which has been quoted as unchanged, four studies have demonstrated reductions in clearance of 19-35%. For highly protein-bound drugs, total clearance is not the appropriate parameter. Free drug clearance is more appropriate since it is independent of changes in protein binding. The literature was reviewed to test the hypothesis that in elderly people, capacity-limited drugs with high protein binding will show decreased free clearance even in the absence of a decrease in total clearance. For these drugs, data for free drug clearance based on measurement of actual free drug concentrations are limited, but suggest that the intrinsic metabolic clearance is impaired in elderly subjects. Four studies of naproxen (f(u) <0.01) have shown reduced free drug clearance of 50% or more. Two studies of valproic acid (f(u) 0.1-0.2) have shown reduced free clearance of 39% and 65%. Two studies of ibuprofen (f(u) <0.01) have shown reduced free clearance of S-ibuprofen of 21% and 28%. There is some indirect evidence for reduced clearance of the highly protein-bound drugs oxaprozin, temazepam, lorazepam, diazepam, phenytoin and warfarin, although studies measuring free concentrations are lacking. Together, the above studies support the hypothesis that the intrinsic metabolic drug clearance is impaired in elderly subjects, in the order of 20-60%, and that this effect is masked if highly protein-bound drugs are assessed using total drug clearance. If the findings are confirmed in future well-designed studies of free drug clearance, there are profound and beneficial implications for dosing of drugs in elderly people. Lower doses are likely to achieve appropriate concentrations, allowing full efficacy but decreased dose-related adverse effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18399712     DOI: 10.2165/00003088-200847050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  134 in total

1.  Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men.

Authors:  J J Crowley; B J Cusack; S G Jue; J R Koup; B K Park; R E Vestal
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

2.  The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions.

Authors:  B Herd; H Wynne; P Wright; O James; K Woodhouse
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

3.  Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels.

Authors:  A L Sherwin; J S Loynd; G W Bock; C D Sokolowski
Journal:  Epilepsia       Date:  1974-12       Impact factor: 5.864

4.  Phenytoin toxicity in a critically ill, hypoalbuminemic patient with normal serum drug concentrations.

Authors:  D F Driscoll; M McMahon; G L Blackburn; B R Bistrian
Journal:  Crit Care Med       Date:  1988-12       Impact factor: 7.598

5.  Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients.

Authors:  A D Woolf; H J Rogers; I D Bradbrook; D Corless
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

6.  Effect of age and gender on disposition of temazepam.

Authors:  M Divoll; D J Greenblatt; J S Harmatz; R I Shader
Journal:  J Pharm Sci       Date:  1981-10       Impact factor: 3.534

7.  The association of age and frailty with paracetamol conjugation in man.

Authors:  H A Wynne; L H Cope; B Herd; M D Rawlins; O F James; K W Woodhouse
Journal:  Age Ageing       Date:  1990-11       Impact factor: 10.668

8.  The influence of age, liver size and enantiomer concentrations on warfarin requirements.

Authors:  H Wynne; L Cope; P Kelly; T Whittingham; C Edwards; F Kamali
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

9.  Oxaprozin pharmacokinetics in the elderly.

Authors:  D J Greenblatt; R Matlis; J M Scavone; G T Blyden; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

10.  Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers.

Authors:  P C Gøtzsche; F Andreasen; C Egsmose; B Lund
Journal:  Scand J Rheumatol       Date:  1988       Impact factor: 3.641

View more
  36 in total

1.  The 'apparent clearance' of free phenytoin in elderly vs. younger adults.

Authors:  Daniel F B Wright; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.

Authors:  Joseph L Tan; Jacques G Eastment; Arjun Poudel; Ruth E Hubbard
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 3.  Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.

Authors:  Andrew J McLachlan; Sally Bath; Vasi Naganathan; Sarah N Hilmer; David G Le Couteur; Stephen J Gibson; Fiona M Blyth
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 4.  Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients.

Authors:  Brendan J Ng; David G Le Couteur; Sarah N Hilmer
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

5.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

6.  Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.

Authors:  Paul K L Chin; Berit P Jensen; Helle S Larsen; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

7.  A unified pharmacokinetic approach to individualized drug dosing.

Authors:  Evan J Begg; Paul K L Chin
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

8.  Combination of micellar electrokinetic and high-performance liquid chromatographies to assess age-related changes in the in vitro metabolism of Fischer 344 rat liver.

Authors:  Yaohua Wang; Joseph B Katzenmeyer; Edgar A Arriaga
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-07-11       Impact factor: 6.053

Review 9.  Guidance for appropriate use of psychotropic drugs in older people.

Authors:  Andreas Capiau; Katrien Foubert; Annemie Somers; Mirko Petrovic
Journal:  Eur Geriatr Med       Date:  2021-01-08       Impact factor: 1.710

10.  Predicted metabolic drug clearance with increasing adult age.

Authors:  Thomas M Polasek; Farhaan Patel; Berit P Jensen; Michael J Sorich; Michael D Wiese; Matthew P Doogue
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.